Podcast

Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

In this episode of Speaking of Urology®, Amar Kishan, MD, highlights findings from phase 3 MIRAGE trial (NCT04384770), which compared Magnetic Resonance Imaging-guided stereotactic body radiotherapy with Computed Tomography-guided stereotactic body radiotherapy in localized prostate cancer. Kishan is an associate professor of radiation oncology and urology and the chief of genitourinary oncology for radiation oncology at University of California, Los Angeles.

Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Ruben Olivares, MD, answers a question during a Zoom video interview
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
1 expert in this video
1 expert in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.